Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients With Recurring Chronic Lymphocytic Leukemia

NCT04895436 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04895436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04895436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients With Recurring Chronic Lymphocytic Leukemia
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Recruiting
Start date
March 28, 2022
Completion date
January 31, 2029
Enrollment
75 (estimated)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia (cll)